Citations (9)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Tobias Engel Ayer Botrel, Márcia Datz Abadi, Laura Chabrol Haas, Cássia Rita Pereira da Veiga, Dominihemberg de Vasconcelos Ferreira & Denis Leonardo Jardim. (2021) Pembrolizumab plus axitinib and nivolumab plus ipilimumab as first-line treatments of advanced intermediate- or poor-risk renal-cell carcinoma: a number needed to treat analysis from the Brazilian private perspective. Journal of Medical Economics 24:1, pages 291-298.
Read now
Read now
Panagiotis Petrou. (2018) A systematic review of economic evaluations of tyrosine kinase inhibitors of vascular endothelial growth factor receptors, mammalian target of rapamycin inhibitors and programmed death-1 inhibitors in metastatic renal cell cancer. Expert Review of Pharmacoeconomics & Outcomes Research 18:3, pages 255-265.
Read now
Read now
Anna M Czarnecka, Cezary Szczylik & Brian Rini. (2014) The use of sunitinib in renal cell carcinoma: where are we now?. Expert Review of Anticancer Therapy 14:9, pages 983-999.
Read now
Read now
Hind T Hatoum, E David Crawford, Sandy Kildegaard Nielsen, Swu-Jane Lin & Dennis C Marshall. (2013) Review of the economic evaluations of hormonal therapy for patients with locally advanced prostate cancer. Expert Review of Pharmacoeconomics & Outcomes Research 13:2, pages 251-259.
Read now
Read now
Articles from other publishers (5)
Chun-Ru Chien, Daniel M. Geynisman, Bumyang Kim, Ying Xu & Ya-Chen Tina Shih. (2018) Economic Burden of Renal Cell Carcinoma—Part I: An Updated Review. PharmacoEconomics 37:3, pages 301-331.
Crossref
Crossref
Dinesh Kumar Chellappan, Jestin Chellian, Zhao Yin Ng, Yan Jinn Sim, Chiu Wei Theng, Joyce Ling, Mei Wong, Jia Hui Foo, Goh Jun Yang, Li Yu Hang, Saranyah Nathan, Yogendra Singh & Gaurav Gupta. (2017) The role of pazopanib on tumour angiogenesis and in the management of cancers: A review. Biomedicine & Pharmacotherapy 96, pages 768-781.
Crossref
Crossref
Robert J. Motzer, Bernard Escudier, Andrew Gannon & Robert A. Figlin. (2017) Sunitinib: Ten Years of Successful Clinical Use and Study in Advanced Renal Cell Carcinoma. The Oncologist 22:1, pages 41-52.
Crossref
Crossref
Sharada H. Sharma, Senthilkumar Thulasingam & Sangeetha Nagarajan. (2016) Chemopreventive agents targeting tumor microenvironment. Life Sciences 145, pages 74-84.
Crossref
Crossref
Bengt Jönsson, Scott Ramsey & Nils Wilking. (2014) Cost effectiveness in practice and its effect on clinical outcomes. Journal of Cancer Policy 2:1, pages 12-21.
Crossref
Crossref